Abstract
Human antimicrobial RNases, which belong to the vertebrate RNase A superfamily and are secreted upon infection, display a wide spectrum of antipathogen activities. In this work, we examined the antifungal activity of the eosinophil RNase 3 and the skin‐derived RNase 7, two proteins expressed by innate cell types that are directly involved in the host defense against fungal infection. Candida albicans has been selected as a suitable working model for testing RNase activities toward a eukaryotic pathogen. We explored the distinct levels of action of both RNases on yeast by combining cell viability and membrane model assays together with protein labeling and confocal microscopy. Site‐directed mutagenesis was applied to ablate either the protein active site or the key anchoring region for cell binding. This is the first integrated study that highlights the RNases’ dual mechanism of action. Along with an overall membrane‐destabilization process, the RNases could internalize and target cellular RNA. The data support the contribution of the enzymatic activity for the antipathogen action of both antimicrobial proteins, which can be envisaged as suitable templates for the development of novel antifungal drugs. We suggest that both human RNases work as multitasking antimicrobial proteins that provide a first line immune barrier.
Highlights
Fungal infections are a threat to hospitalized and immunocompromised patients
The antifungal mechanisms of action of RNase 3 and RNase 7 on Candida albicans were characterized through a variety of methodological approaches
Human antimicrobial RNases, which are secreted upon infection and display a variety of cytotoxic activities, provide a suitable working model
Summary
Fungal infections are a threat to hospitalized and immunocompromised patients. Candida albicans is a major common fungal pathogen in humans that colonizes the skin and the mucosal surfaces of most healthy individuals. Its specific composition, which is predominantly composed of carbohydrates (Chitin, β-1,3 glucan, and β-1,6 glucan), offers resistance to host molecular defense and is impermeable to most potential antifungal drugs (Molero et al 1998; Mayer et al 2013). We used C. albicans as a eukaryotic pathogen model, which has proven to be an appropriate first approach to understand the distinct levels of action of antimicrobial RNases
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.